Translational roadmap from laboratory to clinic
Turning a gene therapy for Hurler syndrome (severe MPS I, MPS I-H) from a laboratory concept into a potential treatment in the clinic requires many carefully planned steps. Each stage, from preclinical models to first-in-human studies and long-term follow up, is designed to protect patient safety and generate robust evidence.
This page outlines the translational roadmap for systemic gene therapy in Hurler syndrome, connecting the preclinical programme to future clinical trials and real-world practice in clear, structured stages.
Gene therapy for Hurler syndrome is investigational. This roadmap describes the typical development pathway and does not imply that any specific programme has achieved regulatory approval or clinical availability.
From idea to evidence
A translational roadmap describes the sequence of work needed to move:
- From laboratory discovery → through preclinical testing → into well designed clinical trials → and finally into routine care, if proven safe and effective.
For Hurler syndrome gene therapy, the roadmap:
- Builds directly on the scientific background and unmet need
- Connects preclinical efficacy and safety to regulatory requirements
- Structures clinical development in stages, with clear decision points
- Emphasises long-term follow up and collaboration with patients, families and clinicians
Showing that the idea can work in principle
Vector design and mechanism
Constructing a vector that carries a functional IDUA transgene and achieves sustained alpha-L-iduronidase expression.
In vitro studies
Demonstrating enzyme production and GAG reduction in relevant cell systems.
Preclinical animal models
Testing the vector in MPS I models to show:
- Increased enzyme activity
- Reduced GAG storage
- Improved organ histology
- Better survival and general health
When these proof-of-concept criteria are met, the programme can move to formal safety and toxicology work.
Formal safety and biodistribution under regulatory standards
At this stage:
Good Laboratory Practice (GLP) toxicology studies
are performed in one or more relevant species, often including:
- •High and low dose groups
- •Multiple time points
- •Detailed safety laboratories and histopathology
Biodistribution and integration profile
Mapping where the vector goes and where the transgene is present. Assessing whether any organs show unexpected exposure or risk.
The aims are to:
- Identify a dose range that is biologically active and acceptably safe in animals
- Characterise target organs for potential toxicity
- Generate the data regulators need to consider a first-in-human study
Making clinical grade gene therapy
To treat even a small number of patients, the programme must:
Develop a scalable manufacturing process
for clinical grade vector
Establish Chemistry, Manufacturing and Controls (CMC) documentation
including:
- Identity and purity of the product
- Potency assays (for example measuring functional enzyme production in vitro)
- Stability and storage conditions
- Release criteria for each batch
This stage ensures that:
- Every dose given in a trial is consistent in quality
- The product meets regulatory standards for human use
- Manufacturing can be repeated reliably if the programme progresses
Planning the first-in-human study
Researchers then work with regulators to:
Preclinical package
Present the preclinical package (efficacy, safety, biodistribution, toxicology, CMC)
Dosing and monitoring
Define the initial dose range and escalation scheme. Agree on safety monitoring, including early stopping rules.
Endpoints
Select primary and secondary endpoints, such as:
- Safety and tolerability
- Enzyme activity and GAG levels
- Organ outcomes and early functional measures
Patient population
Discuss the proposed patient population, such as:
- Pre symptomatic infants identified by newborn screening
- Young children with confirmed Hurler syndrome
- Patients with prior HSCT and residual disease